Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Excited to share 2 year follow-up of SWOG Cancer Research Network S1826: Nivolumab+AVD vs. BV-AVD in Advanced-Stage Classic Hodgkin Lymphoma NEJM Wilmot Cancer Institute nejm.org/doi/full/10.10…

Primera reunión de Grupo GELL y GELTAMO en #ASH24. ASH nos ayuda a conectar y trabajar juntos. ¡El MOMENTUM es ahora! #lymsm #HematologíaEnEspañol

Comenzamos la tercera edición de “Estado actual de la terapia #CART en el tratamiento de los Linfomas”. Este primer módulo con las indicaciones actuales GELTAMO

La #Hematología, la especialidad que lucha por colarse en el podio del #MIR #2MIR25 @sehh_es @sehh_es

Autologous Stem Cell Transplantation for Relapsed/Refractory Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study ashpublications.org/bloodadvances/… 🔬Estudios colaborativos GELTAMO GETH

🔬Mañana intensa y productiva en #GELTAMO2025. Las reuniones de nuestros 5 grupos de trabajo han dado a conocer nuevos proyectos y estudios clave. ¡Seguimos impulsando la investigación y el conocimiento! #investigacion #linfomas

GELTAMO study in #EHA2025 with Raul Cordoba, MD, PhD IMPACT OF AGE, FRAILTY AND COMORBIDITIES IN THE SURVIVAL OF OLDER PATIENTS WITH HODGKIN LYMPHOMA: A RETROSPECTIVE, MULTICENTER STUDY IN SPAIN FROM THE SPANISH LYMPHOMA REGISTRY (RELINF) OF THE SPANISH GROUP OF LYMPHOMA (GELTAMO)

#destacadoSEHH | España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes GELTAMO AbbVie España Hematología HGUGM Vall d'Hebron Mariana Bastos, MD, PhD Pau Abrisqueta Alejandro Martín García-Sancho immedicohospitalario.es/noticia/51673/… a través de IM Médico

GELTAMO en #18ICML CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS: A MULTICENTER STUDY FROM THE SPANISH GROUP GELTAMO Pau Abrisqueta International Conference on Malignant Lymphoma

GELTAMO en #18ICML IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B-CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP #DavidAlonsoCastronuño #NormaGutierrez International Conference on Malignant Lymphoma

#icml2025 Congrats Dr Juan Manuel Sancho for the excellent presentation! GELTAMO Institut Català d'Oncologia

CONGRESS | #18ICML | Juan-Manuel Sancho Hematologia ICO Badalona - Germans Trias i Pujol shares the results from the phase III POLARGO trial of Pola-R-GemOx for the treatment of transplant-ineligible R/R #DLBCL. With Pola-R-GemOx and R-GemOx respectively, Median OS 19.5 mo vs 12.5 mo, Median PFS 7.4 mo vs 2.7 mo,

GELTAMO in #18ICML AGE, FRAILTY, COMORBIDITIES AND FIRST-LINE TREATMENT IMPACT IN SURVIVAL OF ELDERLY HODGKIN LYMPHOMA PATIENTS: GELTAMO RETROSPECTIVE STUDY FROM THE SPANISH GELTAMO GROUP International Conference on Malignant Lymphoma Raul Cordoba, MD, PhD Eva Domingo-Domenech

GELTAMO in #18ICML Primary mediastinal large B-cell lymphoma (PMBCL): a multicentric observational study of Spanish lymphoma group GELTAMO Almudena Cabero Alejandro Martín García-Sancho International Conference on Malignant Lymphoma

GELTAMO in #18ICML Prognostic Impact of Extranodal Infiltration Based on Anatomic Locations at Plasmablastic Lymphoma Diagnosis in a Multicentric Spanish Series (GELTAMO) Fernando Martín Moro Mariana Bastos, MD, PhD International Conference on Malignant Lymphoma

PMBCL outcomes..large database Me he convertido en hincha de GELTAMO !

GELTAMO in #18ICML Zanubrutinib in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Efficacy and Safety of 101 Spanish Patients Treated in the Real-World on Behalf of GELTAMO Antonio Salar Fernando Martín Moro Ana Muntañola International Conference on Malignant Lymphoma

GELTAMO in #18ICML Exploring a New Prognostic Index in 341 Post-Transplant Lymphoproliferative Disorders in the "Rituximab Era": A Retrospective Study from Spanish Lymphoma Group GELTAMO Daniel Gil Alós Ana Jimenez Ubieto International Conference on Malignant Lymphoma

Empezamos con la apertura de centros del REPIFIR!! Un EECC español, con Epcoritamab +/- tafa-lena en primera recaída de DLBCL, guiado por MRD y PET. Gran esfuerzo colectivo de GELTAMO, promovido por GELTAMO con el soporte de AbbVie España, AbbVie y la colaboración de Incyte